Shots:

• The collaboration will deploy Engitix’s ECM platform to identify drug targets for potential future oral integrin drug therapies as treatments for fibrostenotic diseases
• The ECM platform will be used to characterize the expression of drug therapies and cover integrin/ non-integrin expression in fibrostenosis. Morphic will advance therapies for patients with autoimmune- CV- metabolic diseases- as well as fibrosis and cancer by leveraging its MInT technology
• The collaboration will lead towards the expansion of ECM platform by exploring disease indications beyond Engitix in-house programmes- Additionally- Morphic is advancing its pipeline and discovery activities utilizing its MInT technology in collaboration with AbbVie- Janssen and Schrödinger

Click here to­ read full press release/ article | Ref: Businesswire | Image: Engitix